Skip to main content

Table 3 Efficacy Outcomes

From: World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis

Complete Clinical Cure

Study

Patients

Comparison

Follow up

RR

95% CI

p value

Balagon, 2010 [18]

PB

MDT vs. 28 days of RFP + ofloxocin for 4w then 5 months of placebo

6 m

4.2

2.25–7.85

< 0.05

12 m

0.93

0.80–1.09

0.38

Bathe, 1986 [19]

MDT vs. MDT+ clofazimine in alternative days for 6 m

6 m

1.25

0.77–2.04

0.37

24 m

1.09

0.93–1.27

0.29

Orege, 1990 [26]

MDT vs. Modified MDT (MDT + RFP + dapsone)a

6 m

0.76

0.61–0.95

0.02

Clinical Improvement

Study

Patients

Comparison

Follow up

MDT

Control

Rao, 2009 [27]

PB

MDT vs RFP + dapsone + clofazimine (good)

24 m

6/11 (52%)

7/9 (78%)

MDT vs RFP + dapsone + clofazimine (moderate)

3/11 (27%)

2/9 (22%)

MB

MDT vs RFP + dapsone + clofazimine (good)

13/17 (77%)

1/4 (25%)

MDT vs RFP + dapsone + clofazimine (moderate)

3/17 (17%)

None

Sampoonachut, 1997 [36]

MDT vs. MDT + ofloxacin.

36 m

66.70%

73.30%

MDT vs. ofloxacin + clofazimine, then MDT

66.70%

76.50%

Tejasvi, 2006 [39]

MDT vs. RFP + Sparfloxacin + clarithromycin + minocycline

12 m

66.66%

73.92%

Villahermosa, 2004 [40]b

MDT vs. ROM

96 m

22 points

20 points

Relapse

Study

Patients

Comparison

Follow up

RR

95% CI

p value

Balagon, 2010 [18]

PB

MDT vs. 28 days of RFP + ofloxacin for 4w then 5 m of placebo

12 m

1.76

0.16–18.88

0.64

Katoch, 1999 [22]

MDT vs. MDT+ clofazimine

24 m

5

0.24–103.28

0.3

Kumar, 2015 [23]

MDT vs. ROM

24 m

0.5

0.05–5.45

0.57

96 m

1.7

0.94–3.07

0.08

Manickam, 2012 [24]

MDT vs. ROM

6 m

1.43

0.56–3.64

0.46

Fajardo 2009 [30]

MB

MDT 2y vs. MDT 1y + 1 month daily RFP/ofloxacin

144 m

0.51

0.05–5.46

0.58

MDT 2y vs. 1 month daily RFP/ofloxacin

0.11

0.02–0.87

0.04

MDT 2y vs. MDT 1 y

0.05

0.01–0.37

< 0.05

Olivera Penna, 2017 [35]

MDT vs. RFP+ dapsone + clofazimine × 6 m

60 m

0.16

0.02–1.29

0.08

Souza Cunha, 2012 [38]

MDT 1y vs. MDT x 2y

84 m

2.59

0.13–52.17

0.53

MDT 1y vs. MDT + ofloxacin

1.04

0.15–7.10

0.97

MDT 1y vs. ofloxacin + RFP

0.13

0.03–0.51

< 0.05

Villahermosa, 2004 [40]

MDT vs. ROM

96 m

No events reported

BI

Study

Patients

Comparison

Follow up

MD

95% CI

p value

Bathki, 1992 [29]

MB

MDT vs. MDT + vaccine

24 m

1.3

0.48, 2.12

< 0.05

Gunawan 2018 [32]

MDT vs. CDC

3 m

0.03

−0.03,0.09

0.75

Jadav, 1992 [33]

MDT vs. RFP + dapsone + clofazimine

24 m

0.41

0.12, 0.70

< 0.05

Olivera Penna, 2017 [35]

MDT vs. RFP+ dapsone + clofazimine × 6 m

60 m

− 0.15

−1.06,0.76

0.34

Sampoonachut, 1997c [36]

MDT vs. MDT + ofloxacin.

36 m

−0.07

− 0.48, 0.34

0.74

MDT vs. Ofloxacin + clofazimine, then MDT

−0.68

−1.10, − 0.26

< 0.05

Shaw, 2003c [37]

MDT vs. RFP + clofazimine+ acedapsone + dapsone

24 m

0.1

− 0.34, 0.54

0.66

  1. Abbreviations. - BI Bacillary index, CDC Clarithromycin+ dapsone+ clofazimine, m Months, MDT Multidrug treatment, ROM Rifampin, ofloxacin and minocycline
  2. aIncluded a period of direct observation
  3. bMaximum Improvement score at the end of treatment; no other information reported
  4. cSD not reported